Consider Holding Febuxostat in Patients Admitted with CV Disease

September 2018

Please see the February 2019 FDA advisory concerning the increased risk of death with Uloric (Febuxostat).

You'll hear about an advocacy group pushing for withdrawal of the gout med febuxostat (Uloric)...due to concerns it increases mortality.

We know patients with gout are already at elevated CV risk.

And early studies signaled a higher risk of CV events in patients on febuxostat compared to allopurinol...so FDA required a safety trial.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Table of Contents

Antibiotics Don't Expect the New Antibiotic Plazomicin to Be Added to Formulary
Thrombolytics Weigh Thrombolytic Pros and Cons for Submassive Pulmonary Embolism
Bites & Stings Know the Difference Between CroFab and the New Snakebite Antivenom Anavip
Recalls The Valsartan Recall May Shake Up ARB Use at Your Hospital
Antibiotics Continue to Avoid Quinolones When Possible
New Drugs Stick With Clonidine When Using a Non-Opioid to Manage Acute Opioid Withdrawal
Diabetes Don't Jump to Newer Diabetes Meds for Renal Protection Yet
New Drugs Watch for Epidiolex, a New Rx Cannabinoid
Gout Consider Holding Febuxostat in Patients Admitted with CV Disease
New Drugs Hold the Low-Dose Vaginal Estrogen Imvexxy During Hospitalization